A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase not reported
- Study design
- NON RANDOMIZED · PARALLEL · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 14
- Population
- ALL · 60 Years
- Duration
- 2024-07-01 to 2024-10-30
- Intervention
- Subtenon Autologous Platelet-Rich Plasma Injection
- Comparator
- Untreated Fellow Eye
- Outcomes measured
- Change in Retina Pigment Epithelium Atrophy Area (mm²) — Baseline (Week 0) to 2 weeks after the third PRP injection (We…; Retina Pigment Epithelium Atrophy Growth Rate (Square root transformed, mm/year) — Baseline (Week 0) to Week 10 (2 week…; Change in Photoreceptor Loss Area (mm²) — Baseline (Week 0) to Week 10 (2 weeks after the third PRP injection); Photoreceptor Loss Growth Rate (Square root transformed, mm/year) — Baseline (Week 0) to Week 10 (2 weeks after the thi…; Change in Best-Corrected Visual Acuity — Baseline (Week 0) to Week 10 (2 weeks after the third PRP injection); Change in Reading Performance — Baseline (Week 0) to Week 10 (2 weeks after the third PRP injection); Change in Multifocal Electroretinography P1-Wave Amplitude — Baseline (Week 0) to Week 10 (2 weeks after the third PRP…; Change in Multifocal Electroretinography P1-Wave Implicit Time — Baseline (Week 0) to Week 10 (2 weeks after the third…; Change in Vision-Related Quality of Life (NEI-VFQ-25 Score) — Baseline (Week 0) to Week 10 (2 weeks after the third PRP…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.